24.6 C
Vientiane
Sunday, May 25, 2025
spot_img
Home Blog Page 345

SATELLAI Launches World’s Most Connected Smart Dog Collar with Global Coverage and AI-Powered Monitoring

The SATELLAI Collar Sets a New Standard in GPS Tracking, Virtual Fencing, and AI-Driven Pet Care

SHENZHEN, China, April 10, 2025 /PRNewswire/ — SATELLAI, a pioneering force in AI-integrated pet technology, announced today the official launch of the SATELLAI Collar, the most advanced pet wearable designed for indoor and outdoor use. The Collar delivers unmatched connectivity, security, and training support for pet owners worldwide, with state-of-the-art satellite tracking, AI-powered health monitoring, and real-time behavior analysis.

SATELLAI Collar
SATELLAI Collar

“Pet owners deserve technology that enhances their pets’ safety and well-being,” says Mark Mao, Founder and CEO of SATELLAI. “The SATELLAI Collar redefines what’s possible in pet tracking and care, ensuring pets stay safe and healthy. It’s built for real-world conditions—rugged, waterproof, and with a battery life that lasts for days, not hours. Our mission is to give pet owners peace of mind, knowing their dogs are safe and connected, no matter where they roam.”

Next-Generation Pet Tracking & Safety

The SATELLAI Collar revolutionizes boundary control with its dual-antenna build and dual-band positioning, supported by five Global Navigation Satellite Systems, ensuring pinpoint accuracy. Unlike older-generation pet trackers, SATELLAI provides global coverage, operating across 680+ networks in 180+ countries.

Pet owners can create unlimited customizable virtual fences with overlapping and nested boundaries covering up to 100,000 acres. These fences allow pets to roam safely and send instant escape alerts if they stray beyond predefined areas.

AI-Powered Health & Behavior Monitoring

More than just a GPS tracker, the SATELLAI Collar offers a comprehensive AI-driven health and wellness monitoring system, providing pet owners with real-time data on their dog’s activity levels, stress indicators, and overall health. The built-in AI Coach delivers:

  • Personalized care recommendations tailored to the pet’s lifestyle.
  • Nutrition planning to optimize health and weight management.
  • Adaptive training support using real-time feedback mechanisms, including vibration and auditory cues.

Unmatched Durability & Battery Life

The SATELLAI Collar is designed to withstand even the most rugged conditions. It is IP68-rated, waterproof, and dust-resistant, making it perfect for adventurous pets who enjoy rain, mud, or swimming. The collar’s industry-leading battery life lasts up to seven days on a single two-hour charge, surpassing competitors’ daily recharging requirements.

Key Features & Benefits

  • Global, Always-On Connectivity – Dual-antennas and dual-signal transmission with satellite-backed precision across 680+ networks in 180+ countries.
  • AI-Powered Health & Activity Tracking – Real-time monitoring of pet activity, stress, and health indicators.
  • Escape Notifications & Route History – Instant alerts when a pet leaves a safe zone, with detailed tracking history.
  • Customizable Virtual Fencing – Manage overlapping and nested fences for properties up to 100,000 acres.
  • Smart Training Tools – Multiple feedback modes for behavior reinforcement.
  • Rugged & Long-Lasting – Waterproof, dust-resistant, and a 7-day battery life with 2-hour fast charging.

The SATELLAI Collar is priced at $499, with a special 15% discount and a free two-month subscription for initial purchases while supplies last. The Collar can be purchased at https://satellai.com/.

About SATELLAI

SATELLAI enhances pet safety, health, and happiness with innovative technology. Founded by pet lovers, the company creates smart collars and trackers to prevent loss, injury, and health issues. With more advancements ahead, SATELLAI brings peace of mind to pet owners worldwide.

NYSE Content Advisory: Pre-Market update + EU pauses U.S. tariffs for 90 days

NEW YORK, April 10, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins.

 

NYSE_Market_Update_April_10_2025

Kristen Scholer delivers the pre-market update on April 10th

  • The S&P 500 soared nine percent for its third biggest gain in 80 years after President Donald Trump’s tariff tone down spurred a historic rally on Wall Street.  
  • The United States adjusted its tariffs on most countries except China, and this morning, the European Union announced it would pause its countermeasures against the United States for 90 days.
  • Today begins the first of back-to-back inflation reports with forecasters anticipate consumer prices rose 0.1 percent in March from February and 2.6 percent last month from a year ago.

Opening Bell
Breaking Ground celebrates 35 years of building and restoring lives across New York City!

Closing Bell
KeyCorp (NYSE: KEY) marks its bicentennial and 200 years of service to clients and communities. 

Watch NYSE TV Live every weekday 9:00-10:00am ET 

 

NORTH AMERICAN MANUFACTURERS REPORT SHARP PULLBACK DUE TO TARIFFS, WHILE ASIAN SUPPLIERS RUN AT FULL TILT: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX

  • In March, global supply chains spare capacity increased to highest level since May 2020, the height of the COVID-19 pandemic, indicating rapidly worsening conditions for global manufacturers
  • Factories in the U.S., Mexico and Canada retrenched sharply in March due to tariffs, with purchasing activity down the most in Canada
  • UK supplier activity contracting at a rate that has only ever been surpassed twice previously in the last 25 years, signaling considerable manufacturing weakness

CLARK, N.J., April 10, 2025 /PRNewswire/ — GEP Global Supply Chain Volatility Index — a leading indicator tracking demand conditions, shortages, transportation costs, inventories, and backlogs based on a monthly survey of 27,000 businesses — decreased for a third successive month in March to -0.51 and posted its lowest value in almost five years, indicating the highest degree of spare capacity across global supply chains since the height of the COVID-19 pandemic in 2020.

GEP Supply Chain Volatility Index
GEP Supply Chain Volatility Index

A key finding from GEP’s latest data was a sharp decline in the number of companies building buffers into their stocks. Overall, manufacturers’ stockpiling was the lowest in nine years, highlighting caution among procurement leaders worldwide about future demand.

“March’s sharp decline in supplier activity was due to the stifling effect of tariffs and tariff-related uncertainty, which had its strongest impact in North America, where manufacturers reported cutbacks to purchasing activity and inventories,” said John Piatek, vice president, consulting GEP. “Until just last week, most companies had taken a wait-and-see approach. Now, organizations are aggressively exploring every possible way to eliminate costs, push suppliers to absorb tariffs, and de-risk their global supply chains.”

In the U.K., supplier spare capacity rose for the fourth month in succession to a level that has only been surpassed during either the COVID-19 pandemic or global financial crisis period. U.K. factories aggressively destocked and reduced spending during March, suggesting the country’s industrial sector is bracing for a downturn.

Our data showed significant slack across European supply chains in March, although in contrast to the U.K., there were budding signs of recovery for the continent’s industrial sector as demand for raw materials, commodities and components were down by the softest margin in almost three years.

Meanwhile in Asia, supply chains are broadly running at full capacity. In March, there was even a slight uptick in regional procurement activity, driven by China and India.

Interpreting the data:
Index > 50 means growth. The further above 50, the faster the growth
Index < 50 means decreasing. The further below 50, the larger the contraction.

MARCH 2025 KEY FINDINGS

  • DEMAND: Our indicator, which tracks global demand for raw materials, components and commodities, was broadly unchanged during the month and therefore remained close to its long-term average, signaling global purchasing activity was near its historical trend. There remains considerable geographical differences, however, with a worsening of factory input demand in North America contrasting with some pick-up in Europe and Asia.
  • INVENTORIES: Reports of safety stockpiling from manufacturers across the globe decreased in March to their lowest since July 2016 as procurement managers show a strong reluctance to add to their inventories. The data continues to point to the adoption of a “wait-and-see” mentality among buyers as uncertainty regarding worldwide trade conditions remains rife.
  • MATERIAL SHORTAGES: Our global item shortages indicator, which tracks the availability of critical commodities, common inputs and components, remains below its long-term average, signaling robust global material supply levels. This metric implies that vendors have stock to meet orders from their customers.
  • LABOR SHORTAGES: Reports of labor shortages remained contained. Companies are not struggling to process workloads due to staff capacity constraints, according to our backlogs tracker.
  • TRANSPORTATION: Global transportation costs fell to their lowest in the year-to-date. Overall, they were close to their long-term average level in March.

REGIONAL SUPPLY CHAIN VOLATILITY

  • NORTH AMERICA: Index at -0.63, down severely from -0.18, signaling a sharp rise in spare capacity across North American supply chains. U.S., Canadian and Mexican manufacturers retrenched in March.

  • EUROPE: Index ticks up to -0.63, from -0.72, pointing to a still-high level of underutilization across European supply chains. Tentative signs of recovery emerge, however, as weakness in input demand recedes.

  • U.K.: Index slumps to -1.23, a near five-year low, from -0.85, with U.K. procurement managers significantly reducing buying and inventories as the country’s economy shows signs of slowing.

  • ASIA: Index at -0.12, down from 0.00 in February. Overall, Asian supply chains are broadly operating at full capacity.

For more information, visit www.gep.com/volatility.
Note: Full historical data dating back to January 2005 is available for subscription. Please contact economics@spglobal.com.
The next release of the GEP Global Supply Chain Volatility Index will be 8 a.m. ET, May. 13, 2025.

About the GEP Global Supply Chain Volatility Index
The GEP Global Supply Chain Volatility Index is produced by S&P Global and GEP. It is derived from S&P Global’s PMI® surveys, sent to companies in over 40 countries, totaling around 27,000 companies. The headline figure is a weighted sum of six sub-indices derived from PMI data, PMI Comments Trackers and PMI Commodity Price & Supply Indicators compiled by S&P Global.

  • A value above 0 indicates that supply chain capacity is being stretched and supply chain volatility is increasing. The further above 0, the greater the extent to which capacity is being stretched.
  • A value below 0 indicates that supply chain capacity is being underutilized, reducing supply chain volatility. The further below 0, the greater the extent to which capacity is being underutilized.

A Supply Chain Volatility Index is also published at a regional level for Europe, Asia, North America and the U.K. For more information about the methodology, click here.

About GEP
GEP® delivers AI-powered procurement and supply chain solutions that help global enterprises become more agile and resilient, operate more efficiently and effectively, gain competitive advantage, boost profitability and increase shareholder value. Fresh thinking, innovative products, unrivaled domain expertise, smart, passionate people — this is how GEP SOFTWARE™, GEP STRATEGY™ and GEP MANAGED SERVICES™ together deliver procurement and supply chain solutions of unprecedented scale, power and effectiveness. Our customers are the world’s best companies, including more than 1,000 Fortune 500 and Global 2000 industry leaders who rely on GEP to meet ambitious strategic, financial and operational goals. A leader in multiple Gartner Magic Quadrants, GEP’s cloud-native software and digital business platforms consistently win awards and recognition from industry analysts, research firms and media outlets, including Gartner, Forrester, IDC, ISG, and Spend Matters. GEP is also regularly ranked a top procurement and supply chain consulting and strategy firm, and a leading managed services provider by ALM, Everest Group, NelsonHall, IDC, ISG and HFS, among others. Headquartered in Clark, New Jersey, GEP has offices and operations centers across Europe, Asia, Africa and the Americas. To learn more, visit www.gep.com.

About S&P Global
S&P Global (NYSE: SPGI) S&P Global provides essential intelligence. We enable governments, businesses and individuals with the right data, expertise and connected technology so that they can make decisions with conviction. From helping our customers assess new investments to guiding them through ESG and energy transition across supply chains, we unlock new opportunities, solve challenges and accelerate progress for the world. We are widely sought after by many of the world’s leading organizations to provide credit ratings, benchmarks, analytics and workflow solutions in the global capital, commodity and automotive markets. With every one of our offerings, we help the world’s leading organizations plan for tomorrow, today.

Disclaimer
The intellectual property rights to the data provided herein are owned by or licensed to S&P Global and/or its affiliates. Any unauthorised use, including but not limited to copying, distributing, transmitting or otherwise of any data appearing is not permitted without S&P Global’s prior consent. S&P Global shall not have any liability, duty or obligation for or relating to the content or information (“Data”) contained herein, any errors, inaccuracies, omissions or delays in the Data, or for any actions taken in reliance thereon. In no event shall S&P Global be liable for any special, incidental, or consequential damages, arising out of the use of the Data. Purchasing Managers’ Index™ and PMI® are either trade marks or registered trade marks of S&P Global Inc or licensed to S&P Global Inc and/or its affiliates.

This Content was published by S&P Global Market Intelligence and not by S&P Global Ratings, which is a separately managed division of S&P Global. Reproduction of any information, data or material, including ratings (“Content”) in any form is prohibited except with the prior written permission of the relevant party. Such party, its affiliates and suppliers (“Content Providers”) do not guarantee the accuracy, adequacy, completeness, timeliness or availability of any Content and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such Content. In no event shall Content Providers be liable for any damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with any use of the Content.

Media Contacts

Derek Creevey

Joe Hayes

S&P Global Market Intelligence

Director, Public Relations

Principal Economist

Corporate Communications

GEP

S&P Global Market Intelligence

Email: Press.mi@spglobal.com

Phone: +1 646-276-4579

Phone: +44-1344-328-099

Email:
derek.creevey@gep.com

Email:
joe.hayes@spglobal.com

 

GEP Global Supply Chain Volatility Index
GEP Global Supply Chain Volatility Index

 

 

Sensodyne Tackles Widespread Tooth Sensitivity in Malaysia with Fresh Mint Launch and Nationwide “A Happy Mouth is… a Happy Mind” Campaign in conjunction with World Oral Health Day!

KUALA LUMPUR, Malaysia, April 10, 2025 /PRNewswire/ — A new survey* conducted by Haleon, a global leader in consumer health, reveals a significant public health concern in Malaysia: tooth sensitivity. The survey of 248 Malaysians showed that a staggering 69% experience regular tooth sensitivity, with 61.8% enduring the discomfort rather than seeking dental treatment. Sensodyne, Malaysia’s #1 sensitivity toothpaste brand*, is re-launching its Fresh Mint toothpaste with a new and improved formula that provides long-lasting relief and encourages Malaysians to stop enduring and start living life worry-free from sensitivity – because Why Tahan?

Sensodyne Tackles Widespread Tooth Sensitivity in Malaysia with Fresh Mint Launch and Nationwide "A Happy Mouth is… a Happy Mind" Campaign in conjunction with World Oral Health Day!
Sensodyne Tackles Widespread Tooth Sensitivity in Malaysia with Fresh Mint Launch and Nationwide “A Happy Mouth is… a Happy Mind” Campaign in conjunction with World Oral Health Day!

The survey, conducted among the 18-40 age-group, showed that younger generations are highly affected by this issue. A total of 38.4% of the respondents were aged 26-40, while 34.6% belonged to the 18–25 age category, indicating a need for an increased awareness and effective solutions for sensitive teeth across all age groups.

This common condition disrupts the everyday habits of most Malaysians, with cold foods (58.5%) being the leading cause of sensitivity, followed by sweets and hot drinks, based on the survey. These findings highlight how tooth sensitivity prevents individuals from fully enjoying everyday pleasures. Alarmingly, only 13.1% actively address sensitivity by brushing their teeth to relieve discomfort, reflecting low awareness of best practices.

In response to this widespread issue, Sensodyne has announced the launch of Sensodyne Fresh Mint. This new toothpaste, specially developed with an improved formula, provides lasting relief and allows Malaysians to live life without the fear of sensitivity. Sensodyne Fresh Mint offers a range of benefits to tackle sensitivity:

  • 24-Hour Protection: With continued use and twice daily brushing, enjoy your favourite foods and drinks throughout the day without irritation.
  • Lasting freshness: Sensodyne Fresh Mint with improved formulation provides lasting freshness with regular use.

Triple-Action Cleaning Technology: This innovative formula polishes teeth, removes surface stains, and brushes away bacteria for a cleaner, healthier smile.

Sensodyne’s effectiveness is further validated by a Real-World Evidence study published in the International Journal of Environmental Research and Public Health (IJERPH). The Dentine Hypersensitivity Experience Questionnaire (DHEQ) study identified that:

  • 100% of regular Sensodyne users expressed daily satisfaction.
  • 98% reported improvement in their sensitivity symptoms.

“Too many Malaysians endure the discomfort of tooth sensitivity, missing out on simple joys like a refreshing iced coffee or a scoop of ice cream. Instead of addressing the root cause, many wait for the pain to pass. These findings underscore the urgent need for effective solutions and greater awareness around sensitivity. That’s why Sensodyne, in collaboration with the Malaysian Dental Association, is intensifying efforts to raise awareness and promote early intervention – because if left untreated, sensitivity can lead to more serious dental issues,” shared Law Chen, Marketing Director at Haleon Malaysia, Singapore and Brunei.

Dr Mohd Salman bin Masri, a Periodontist representing Malaysian Dental Association (MDA) echoed this sentiment: “Tooth sensitivity is more than just a minor inconvenience – it can signal deeper oral health issues. Yet, many Malaysians endure it without realising how much it affects their daily lives. According to a real-life study recently published in the International Journal of Environmental Research and Public Health, 93% of respondents said sensitivity takes the joy out of eating and drinking, impacting both physical comfort and emotional well-being.  That’s why it’s crucial to address sensitivity early – right when you first feel it. Ignoring it could lead to bigger problems down the line.”

To commemorate World Oral Health Day, Sensodyne is launching a nationwide campaign “A Happy Mouth is…A Happy Mind” to unite Malaysians. As part of this initiative, Sensodyne is collaborating with the Malaysian Dental Association to offer one month of complimentary dental check-ups across more than 500 clinics in Malaysia from 21 April to 21 May 2025.

Sensodyne Fresh Mint is available nationwide at pharmacies, dental clinics, minimarkets, supermarkets, and hypermarkets and provision stores

To learn more about the campaign, visit www.sensodyne.com.my or follow Sensodyne Malaysia’s Facebook and Instagram accounts.

-Ends-

*“GlaxoSmithKline Consumer Healthcare Sdn. Bhd. calculation based in part on data reported by NIQ through its Retail Index Service for the Sensitive segment within the Toothpaste category for the 12 months period ending April 2023, for the Total Malaysia Market. (Copyright © 2023, NIQ.)”

Tadjoedin et al. A Real-World Study on the Quality of Life of Consumers with Dentine Hypersensitivity and the Benefits of Hypersensitivity Toothpaste Use. Int. J. Environ. Res. Public Health 2025, 22, 175. https://doi.org/10.3390/ijerph22020175 

About Haleon

Haleon (LSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories – Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands – such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, Parodontax and Centrum – are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com   

About Haleon Malaysia

Haleon (LSE: HLN) is a global leader in consumer health, with brands trusted by millions of consumers globally. Haleon Malaysia employs over 500 people whose purpose is to deliver better everyday health with humanity. With market leading positions in oral care, pain relief, and wellness, we work closely with pharmacists, physicians, and retailers to increase awareness of everyday health issues and concerns and emphasise the importance of self-care. Haleon’s Hulu Kelang site in Kuala Lumpur also supplies countries around the world with high quality and innovative consumer healthcare products, such as Panadol, ENO and Polident.

 

Hyundai Mobis Seeks Open Innovation Opportunities for Mobility in Detroit

  • Hyundai Mobis held Mobis Mobility Day in Detroit … introducing its business vision and investment status under the theme of “Mobis in Global.”
  • Exploring local collaboration and business opportunities in Detroit, which is home to big 3 automaker and recently emerging as a key hub for mobility startups.
  • It is expanding the discovery of outstanding startups and strategic investment performance … strengthening support for business proofs of concept, led by MVSV, its US-based investment subsidiary.

SEOUL, South Korea, April 10, 2025 /PRNewswire/ — Hyundai Mobis (KRX 012330) held an investment presentation for startups in North America, setting out to secure a future mobility technology alliance. The company announced on 10 that it held the 4th annual Mobis Mobility Day in Detroit, home to the automotive industry. The event had originally been held in Silicon Valley every year. Mobis Mobility Day is an event where Hyundai Mobis introduces its business vision and investment status to global startups, academia, and investors.

Based on its automobile manufacturing infrastructure, Detroit is emerging as a hub for a large number of mobility startups armed with AI and software, as well as production and quality control capabilities.

In this event, these regional characteristics led to many presentations by promising local startups Hyundai Mobis invited. It is reported that in-depth discussions were made regarding mobility trends, particularly in the fields of robotics and cleantech.

Hyundai Mobis changed the venue from Silicon Valley to Detroit this year, considering that its recent global orders have been concentrated on North American customers. The company also considered that by expanding investment and cooperation with promising local startups and jointly developing superior technologies with them, it would be able to promote its products to customers more easily in the future.

During the event, Hyundai Mobis introduced its latest innovations in software-defined vehicle (SDV), electrification, and automotive electronics under the theme of “Mobis in Global,” with presentations on its business vision, open innovation achievements, and investment strategies. It is reported that the event was a great success, attracting over 200 local customer and startup officials. Presentations were given by employees of Mobis Technical Center of America, providing an engaging and informative experience.

“It is becoming important to discover outstanding global startups and make strategic investments to secure innovative technologies that will lead the paradigm shift in mobility,” said Mitchell Yun, investment manager at Mobis Ventures Silicon Valley (MVSV), the organizer of the event. “This year, we will expand our support for business proofs of concept (PoCs), including technology and business feasibility reviews, and strengthen our collaboration to preempt the market.” 

Hyundai Mobis launched Mobis Ventures Silicon Valley, its open innovation base, in Silicon Valley in 2018, and the cumulative amount of money it has invested in startups exceeded 200 billion won last year. Last year, the company made a new investment of 15 million dollars in the US semiconductor company Elevation Microsystems, and in 2020, it invested in the UK’s Envisics and is currently collaborating with it on augmented reality-based head-up display (AR-HUD) technology. It also continues to cooperate with promising companies in the core technology fields of future mobility, including Zendar, a developer of high-performance image radars for autonomous driving, LightIC, an AI-based semiconductor-type lidar company, and Sonatus, a software platform company.

About Hyundai Mobis

Hyundai Mobis is the global no. 6 automotive supplier, headquartered in Seoul, Korea. Hyundai Mobis has outstanding expertise in sensors, sensor fusion in ECUs and software development for safety control. The company’s products also include various components for electrification, brakes, chassis and suspension, steering, airbags, lighting, and automotive electronics. Hyundai Mobis operates its R&D headquarters in Korea, with four technology centers in the United States, Germany, China, and India. For more information, please visit the website at http://www.mobis.com.

Media Contact 
Choon Kee Hwang: ckhwang@mobis.com
Jihyun Han: jihyun.han@mobis.com

 

Standard Chartered and OKX launch world-leading collateral mirroring programme

  • In collaboration with Franklin Templeton, the programme will enable crypto and tokenised money market funds as collateral.
  • The programme will see leading institutions, such as Brevan Howard Digital, onboard onto this pioneering programme.

DUBAI, UAE, April 10, 2025 /PRNewswire/ — Standard Chartered and OKX, a leading cryptocurrency exchange and global onchain technology company, today announced the launch of a ground-breaking, world-leading collateral mirroring programme, enabling institutional clients to utilise cryptocurrencies and tokenised money market funds as off-exchange collateral for trading. This initiative significantly enhances security and capital efficiency for institutional clients by using a Globally Systemically Important Bank (G-SIB) as the custodian for their collateral.

Margaret Harwood-Jones, Global Head of Financing and Securities Services at Standard Chartered said: “We understand the critical importance of robust and secure custody solutions, especially in the evolving digital asset landscape, and our collaboration with OKX to enable the use of cryptocurrencies and tokenised money market funds as collateral represents a significant step forward in providing institutional clients with the confidence and efficiency they need. By leveraging our established custody infrastructure, we are ensuring the highest standards of security and regulatory compliance, fostering greater trust in the digital asset ecosystem.”

The collateral mirroring capability has been launched as a Pilot within the Dubai Virtual Asset Regulatory Authority’s (VARA) regulatory framework, and it allows clients to benefit from enhanced protection against counterparty risk, a significant concern in the current digital asset markets. Standard Chartered acts as the independent, regulated custodian in the Dubai International Financial Centre (DIFC), regulated by the Dubai Financial Services Authority, ensuring the safe storage of the assets used as collateral, while OKX, through its VARA regulated entity, manages collateral and facilitates transactions. Franklin Templeton will be the first in a series of money market funds that will be offered under the OKX-SCB programme.

Hong Fang, President of OKX, said: “As the digital assets ecosystem becomes more ingrained within traditional finance, we strive to both drive growth and safeguard client assets in the most capital efficient manner. By leveraging Standard Chartered’s position as a top custodian globally, as well as OKX’s market leadership in cryptocurrency trading, the partnership sets an industry standard for current and potential institutional clients to deploy trading capital at scale in a trusted environment.”

Franklin Templeton, a recognised leader in tokenisation and real world assets (RWA), continues to innovate by leveraging blockchain technology to deliver cutting-edge solutions to customers and clients. Through this collaboration, OKX clients will gain access to on-chain assets developed by Franklin Templeton’s Digital Assets Team, seamlessly integrating them into their financial and operational structures.  

Roger Bayston, Franklin Templeton Head of Digital Assets, says “Leveraging blockchain technology, our platform is built to support the dynamic and ever-evolving  financial ecosystem. We take an authentic approach, from directly investing in blockchain assets to developing innovative solutions with our in-house team. By ensuring assets are minted on-chain, we enable true ownership, allowing them to move and settle at blockchain speed – eliminating the need for traditional infrastructure.”

Brevan Howard Digital, the dedicated crypto and digital asset division of Brevan Howard, a leading global alternative investment manager, is among the first few institutions to onboard onto this pioneering programme, highlighting the importance of such capabilities being offered by a leading international cross-border bank and a highly reputable global exchange.

Ryan Taylor, Group Head of Compliance at Brevan Howard and CAO of Brevan Howard Digital, commented: “This programme is the latest example of the continued innovation and institutionalisation of the industry. As a significant investor in the digital assets space, we are thrilled to partner with industry leaders to further grow and evolve the crypto ecosystem globally.”

Previous press releases:

Sep 2024: Standard Chartered launches digital asset custody service in the UAE

Oct 2024: OKX names Standard Chartered as institutional third-party custody partner | Standard Chartered

About OKX

OKX is a leading global crypto exchange. Trusted by more than 60 million global users, OKX is known for being one of the fastest and most reliable crypto apps in the world.

As a top brand partner of English Premier League champions Manchester City FC, McLaren Formula 1 and Olympian Scotty James, OKX aims to supercharge the fan experience with new engagement opportunities. OKX is also the top partner of the Tribeca Festival as part of an initiative to bring more creators into web3.

OKX is committed to transparency and security and publishes its Proof of Reserves on a monthly basis. To learn more about OKX, download our app or visit: okx.com.

Disclaimer

About Brevan Howard Digital

Brevan Howard Digital (“BH Digital”) is the dedicated crypto and digital asset division of Brevan Howard, providing institutional investors access to the wide range of diverse opportunities presented by the structural disruption and innovation of blockchain technology. BH Digital offers unconstrained, alpha-centric, and diversified exposure to investment opportunities across the digital asset ecosystem via a multi-manager, multi-strategy approach across both private and public markets. The 60+ member team manages more than $2bn and operates in 8 offices worldwide. For more information, visit www.brevanhoward.com/brevanhoward-digital/.

About Standard Chartered

We are a leading international banking group, with a presence in 53 of the world’s most dynamic markets. Our purpose is to drive commerce and prosperity through our unique diversity, and our heritage and values are expressed in our brand promise, here for good.

Standard Chartered PLC is listed on the London and Hong Kong stock exchanges.

For more stories and expert opinions please visit Insights at sc.com. Follow Standard Chartered on X, LinkedIn, Instagram and Facebook.

About Franklin Templeton 

Franklin Resources, Inc. [NYSE:BEN] is a global investment management organization with subsidiaries operating as Franklin Templeton and serving clients in over 150 countries. Franklin Templeton’s mission is to help clients achieve better outcomes through investment management expertise, wealth management and technology solutions. Through its specialist investment managers, the company offers specialization on a global scale, bringing extensive capabilities in fixed income, equity, alternatives and multi-asset solutions. With more than 1,500 investment professionals, and offices in major financial markets around the world, the California-based company has over 75 years of investment experience and $1.58 trillion in assets under management as of February 28, 2025. For more information, please visit franklintempleton.com and follow us on LinkedIn, X and Facebook

All investments, including money funds, involve risk, including loss of principal. There are risks associated with the issuance, redemption, transfer, custody, and record keeping of shares maintained and recorded primarily on a blockchain. For example, shares that are issued using blockchain technology would be subject to risks, including the following: blockchain is a rapidly-evolving regulatory landscape, which might result in security, privacy or other regulatory concerns that could require changes to the way transactions in the shares are recorded.

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ — Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS). The collaboration leverages Nona’s proprietary H2L2 Harbour Mice® platform to identify next-generation therapeutic candidates for breast cancer.

Nona Biosciences’ proprietary Harbour Mice® platform employs transgenic mice to generate fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization. Combined with the single B cell cloning technology, this platform offers a powerful approach to developing therapeutic antibodies and accelerating drug discovery and development. To date, Harbour Mice® platform has been applied in more than 250 drug discovery programs across multiple therapeutic areas and has been widely recognized by global partners.

“We are pleased to collaborate with Atossa Therapeutics to discover next-generation antibody therapies for breast cancer,” said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences. “This partnership highlights the value of our proprietary Harbour Mice® platform and reflects the industry’s growing demand for innovative antibody discovery solutions. With Nona’s industry-leading technology and expertise, we look forward to supporting Atossa’s exploration of antibody-based approaches within their oncology pipeline.” 

About Nona Biosciences

Nona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing a total solution from “Idea to IND” (“I to ITM“), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team.

Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: www.nonabio.com.

 

Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China’s first hemophilia B gene therapy, was officially approved

SHANGHAI, April 10, 2025 /PRNewswire/ — Belief BioMed (“BBM”) and Takeda China today jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with moderate to severe hemophilia B (congenital coagulation factor IX deficiency). As the first approved hemophilia B gene therapy in China1, BBM-H901 is developed and manufactured by BBM, and Takeda China is responsible for its commercialization in mainland China, Hong Kong and Macau. The two parties will integrate their respective resource advantages to accelerate the provision of this breakthrough gene therapy to patients and jointly open up a new landscape in the field of hemophilia B treatment.

Dr. Xiao Xiao, Co-founder, Chairman and Chief Science Officer of BBM, said: “BBM has always been committed to R&D and innovation in the field of cutting-edge gene therapy, and is dedicated to filling unmet medical needs. The approval of BBM-H901 is an important milestone in the development of BBM. As the first hemophilia B gene therapy drug independently developed in China1, BBM-H901 will provide a new treatment option for hemophilia B patients, which is expected to provide patients with an innovative treatment solution and help them return to a normal life. BBM will work together with Takeda China to accelerate the rapid implementation of this innovative therapy. In the future, BBM will strive to accelerate the overseas commercialization process of BBM-H901, hoping to benefit more hemophilia B patients. “

Sean Shan, Senior Vice President of Takeda Pharmaceutical and President of Takeda China, said: “Takeda is honored to collaborate with BBM to bring the first locally developed hemophilia B gene therapy1 to the Chinese patients with hemophilia B. The approval of BBM-H901 will further enrich our portfolio in hemophilia and rare disease areas, and will help more patients to benefit from innovative treatments. In the future, Takeda China will continue to deepen our strategic cooperation with local partners, to accelerate the commercialization of more breakthrough therapies, ensure China’s medical innovation can benefit more patients and contribute to the high-quality development of China’s rare disease industry.”

Hemophilia B is an inherited bleeding disorder caused by the deficiency of factor IX (FIX)2. For a long time, patients can only rely on prothrombin complex concentrate (PCC) or FIX as a replacement therapy3,4. Persistent and frequent bleeding can easily lead to damage of joint structure and function, resulting in a high disability rate5. This not only brings great physical pain and inconvenience to patients, but also comes with the risk of infection, blood clots, etc.3,4. The high medical treatment costs also bring a heavy and constant economic burden on the patient’s family.

BBM-H901, based on a recombinant adeno-associated virus (rAAV) vector, can deliver the optimized human coagulation FIX gene into liver cells of patients. Then, coagulation FIX is continuously expressed and secreted into the bloodstream using the host cell gene transcription system, thereby promoting coagulation.  

Professor Zhang Lei from the Blood Disease Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), leading investigator of the registered clinical study of BBM-H901, said: “The traditional treatment of hemophilia B requires frequent intravenous injections, and the factor level fluctuates with the half-life of exogenous coagulation factors. Some patients are also at risk of developing inhibitors, leading to reduced treatment effectiveness. The approval of BBM-H901 has brought revolutionary hope to Chinese patients with hemophilia B. By a single dosing, the risk of bleeding and joint damage can be reduced, and patients are back to a normal life. We believe that with the continuous breakthrough of scientific research and the accumulation of clinical experiences, the treatment of hemophilia will enter a new era and patients will enjoy a higher quality of life.”

In 2019, the first Investigator-initiated Trial (IIT) of BBM-H901 was launched. In 2022, the research results of IIT were successively published on international authoritative journals, The Lancet-Hematology and The New England Journal of Medicine5,6. Ten adult patients with moderate to severe hemophilia B were included in the study, with a median follow-up of 58 weeks after gene therapy, achieving a mean FIX activity of 36.9 IU/dL (one Stage Assay actin FSL aPTT reagent). There were no serious adverse events (SAEs) during the follow-up process, and there were no grade 3-4 adverse events (AEs)5.  The long-term follow-up results of more than 3 years were orally presented at the 2024 International Society on Thrombosis and Haemostasis (ISTH) Congress. Compared with the published data in 2022, the patient’s FIX activity remained stable at all follow-up nodes. No drug-related SAEs, thrombotic events, nor inhibitors were observed8.

In August 2021, the Investigational New Drug (IND) application of BBM-H901 was approved in China. In August 2022, BBM-H901 obtained the Breakthrough Therapy Designation by the Center for Drug Evaluation, the National Medical Products Administration7, and later on Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA). In 2024, BBM-H901 obtained the Rare Pediatric Disease Designation (RPDD) from the FDA and the Advanced Therapy Medical Products (ATMP) from the European Medicines Agency (EMA).

In December 2024, BBM released the results of the Phase III clinical study at the 66th Annual Meeting of the American Society of Hematology (ASH). The results showed that after 52 weeks of follow-up, the mean annualized bleeding rate (ABR) of the participants was 0.6, the average FIX activity reached 55.08 IU/dL (one Stage Assay SynthaSIL aPTT reagent), and the average number of infusions of FIX drug decreased from 58.2 times/year before gene therapy treatment to 2.9 times/year after that. Twenty-one of the 26 participants (80.8%) had no bleeding events after treatment, and all participants had no SAEs8. The study is still in the process of continuous follow-up.

###

About Belief BioMed

Belief BioMed Inc. (BBM) is a global biotech company that integrates the research and development (R&D), manufacturing and clinical application of gene therapy products. The company is committed to providing innovative and more effective gene therapies for severe genetic and chronic diseases through safe and efficient viral vector technology. BBM has developed hundreds of key vector technologies, including HEK293 cell suspension serum-free culture process and full-scale chromatography purification process, and has established a commercial production platform for gene therapy drugs. The company has been building up its capabilities in a variety of fields including novel AAV capsids targeting different tissues, efficient transgene expression cassette design, and advanced clinically applicable vector manufacturing process. It has also established an extensive R&D pipeline covering a wide range of unmet clinical needs in different therapeutic areas such as hemophilia, DMD, Parkinson’s disease, osteoarthritis, etc. Several product pipelines have entered clinical studies or submitted Investigational New Drug (IND). The Biologics License Application (BLA) of a gene therapy for the treatment of adult patients with hemophilia B, has been approved by the NMPA of China. For more information, visit www.beliefbiomed.com.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

[1] Up to April 2025. https://www.nmpa.gov.cn/yaopin/index.html

[2] Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association / Hemophilia Treatment Center Collaborative Network of China. Chinese guidelines on the treatment of hemophilia (version 2020). Chin J Hematol..2020;41(4):265-271

[3] Mortensen GL,et al. Haemophilia. 2018;862–872

[4] Srivastava A, et al. Haemophilia. 2020;001–158.P95

[5] Xue F, et al. Lancet Haematol. 2022 Jul;9(7):e504-e513

[6] Xue F, et al. N Engl J Med. 2022 Oct 27;387(17):1622-1624

[7] https://www.cde.org.cn/main/xxgk/listpage/da6efd086c099b7fc949121166f0130c

[8] Feng X,et al. 2024 ASH. Poster 3582